Pegaspargase: A review in acute lymphoblastic leukaemia
(View Complete Item Description)This resource is a video abstract of a research paper created by Research Square on behalf of its authors. It provides a synopsis that's easy to understand, and can be used to introduce the topics it covers to students, researchers, and the general public. The video's transcript is also provided in full, with a portion provided below for preview: "Designed to treat acute lymphoblastic leukaemia, or ALL, pegaspargase is an important and effective treatment option for both paediatric and adult patients. Pegaspargase is a modified form of the anti-ALL enzyme therapy L -asparaginase, derived mainly from E. coli . Unlike the native enzyme, pegaspargase is conjugated with polyethylene glycol , or pegylated—which offers various advantages, such as providing pegaspargase with a prolonged circulation time, allowing for less frequent administration - every two weeks. And it may reduce immunogenicity compared with native (or non-pegylated) L-asparaginase. Extensive evidence shows that, in adults and children newly diagnosed with ALL, intramuscular or intravenous administration of pegaspargase is an effective first-line treatment as part of a multi-agent chemotherapy regimen. It is also beneficial in patients with relapsed ALL who have hypersensitivity to E. coli L-asparaginase..." The rest of the transcript, along with a link to the research itself, is available on the resource itself.
Material Type: Diagram/Illustration, Reading